| Pulmonary arterial hypertension
Tracleer vs Tyvaso
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Tracleer vs Tyvaso with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTyvaso has a higher rate of injection site reactions vs Tracleer based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tyvaso but not Tracleer, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tracleer
Tyvaso
At A Glance
Oral
Twice daily
Endothelin receptor antagonist
Oral inhalation
4 times daily
Prostacyclin analogue
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
- Pulmonary hypertension due to interstitial lung disease
Dosing
Pulmonary arterial hypertension Adults and patients >12 years and >40 kg: 62.5 mg orally twice daily for 4 weeks, then 125 mg twice daily; patients >12 years and <=40 kg: 62.5 mg twice daily; pediatric patients <=12 years: weight-based dosing ranging from 16 mg to 64 mg twice daily.
Pulmonary arterial hypertension, Pulmonary hypertension due to interstitial lung disease Initial dose: 3 breaths (18 mcg) per treatment session 4 times daily via the Tyvaso Inhalation System; if not tolerated, reduce to 1-2 breaths. Increase by 3 breaths per session every 1-2 weeks as tolerated to target maintenance dose of 9-12 breaths per session 4 times daily.
Contraindications
- Pregnancy
- Concomitant use with cyclosporine A
- Concomitant use with glyburide
- Hypersensitivity to bosentan or any component of the product
—
Adverse Reactions
Most common (>=3%) Respiratory tract infection, headache, edema, chest pain, syncope, flushing, hypotension, sinusitis, arthralgia, abnormal serum aminotransferases, palpitations, anemia
Serious Hepatotoxicity, embryo-fetal toxicity, fluid retention, decreased sperm counts, decreases in hemoglobin and hematocrit
Postmarketing Angioedema, unexplained hepatic cirrhosis, liver failure, hypersensitivity/DRESS/anaphylaxis, thrombocytopenia, rash, jaundice, anemia requiring transfusion, neutropenia, leukopenia, nasal congestion, autoimmune hepatitis
Most common (>=4%) Cough, headache, throat irritation/pharyngolaryngeal pain, nausea, flushing, syncope
Serious Decrease in systemic blood pressure, bleeding
Postmarketing Angioedema
Pharmacology
Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB, blocking the vasoconstrictive and proliferative effects of endothelin-1, a neurohormone elevated in plasma and lung tissue of patients with PAH.
Treprostinil is a prostacyclin analogue whose major pharmacologic actions are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tracleer
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Tyvaso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Tracleer
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Tyvaso
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Tracleer
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Tyvaso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Janssen CarePath Oral PAH Savings Program: TracleerCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TracleerView full Tracleer profile
TyvasoView full Tyvaso profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.